Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Correction
space
 arrow  Table of Contents                
space
 arrow  Full Text of this article Free
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Summary for Patients (PDF)
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Qaseem, A.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

CLINICAL GUIDELINES

Screening for Hereditary Hemochromatosis: A Clinical Practice Guideline from the American College of Physicians

right arrow Amir Qaseem, MD, PhD, MHA; Mark Aronson, MD; Nick Fitterman, MD; Vincenza Snow, MD; Kevin B. Weiss, MD, MPH; Douglas K. Owens, MD, MS, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians*

4 October 2005 | Volume 143 Issue 7 | Pages 517-521

Hereditary hemochromatosis is a genetic disorder of iron metabolism. Diagnosis of hereditary hemochromatosis is usually based on a combination of various genetic or phenotypic criteria. Decisions regarding screening are difficult because of the variable penetrance of mutations of the HFE gene and the absence of any definitive trials addressing the benefits and risks of therapeutic phlebotomy in asymptomatic patients or those with only laboratory abnormalities. The purpose of this guideline is to increase physician awareness of hereditary hemochromatosis, particularly the variable penetrance of genetic mutations; aid in case finding; and explain the role of genetic testing. This guideline provides recommendations based on a review of evidence in the accompanying background paper by Schmitt and colleagues. The target audience for this guideline is internists and other primary care physicians. The target patient population is all persons who have a probability or susceptibility of developing hereditary hemochromatosis, including the relatives of individuals who already have the disease.

*This paper, written by Amir Qaseem, MD, PhD, MHA; Mark Aronson, MD; Nick Fitterman, MD; Vincenza Snow, MD; Kevin B. Weiss, MD, MPH; and Douglas K. Owens, MD, MS, was developed for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians (ACP): Douglas K. Owens, MD, MS (Chair); Mark Aronson, MD; Patricia Barry, MD, MPH; Donald E. Casey Jr., MD, MPH, MBA; J. Thomas Cross Jr., MD, MPH; Nick Fitterman, MD; E. Rodney Hornbake, MD; Katherine D. Sherif, MD; and Kevin Weiss, MD, MPH (Immediate Past Chair). Approved by the ACP Board of Regents on 16 July 2005.

Author and Article Information
space

From the American College of Physicians, Philadelphia, Pennsylvania; Beth Israel Deaconess Medical Center, Boston, Massachusetts; North Shore Medical Group, Huntington, New York; VA Palo Alto Health Care System and Stanford University, Stanford, California; and Hines VA Hospital and Northwestern University, Chicago, Illinois.

Note: Clinical practice guidelines are "guides" only and may not apply to all patients and all clinical situations. Thus, they are not intended to override clinicians' judgment. All ACP clinical practice guidelines are considered automatically withdrawn or invalid 5 years after publication, or once an update has been issued.

Annals of Internal Medicine encourages readers to copy and distribute this paper, providing such distribution is not for profit. Commercial distribution is not permitted without the express permission of the publisher.

Grant Support: Financial support for the development of this guideline comes exclusively from the ACP operating budget.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Amir Qaseem, MD, PhD, MHA, American College of Physicians, 190 N. Independence Mall West Philadelphia, PA 19106; e-mail, aqaseem{at}acponline.org.

Current Author Addresses: Drs. Qaseem and Snow: American College of Physicians, 190 N. Independence Mall West, Philadelphia, PA 19106.

Dr. Aronson: 330 Brookline Avenue, Boston, MA 02215.

Dr. Fitterman: 120 New York Avenue, Huntington, NY 11743.

Dr. Weiss: 151H, PO Box 5000, Hines, IL 60141.

Dr. Owens: 117 Encina Commons, Stanford, CA 94305.


Related articles in Annals:

Clinical Guidelines
Screening Primary Care Patients for Hereditary Hemochromatosis with Transferrin Saturation and Serum Ferritin Level: Systematic Review for the American College of Physicians
Brian Schmitt, Robert M. Golub, AND Richard Green
Annals 2005 143: 522-536. [ABSTRACT][SUMMARY][Full Text]  

Summaries for Patients
Screening for Hereditary Hemochromatosis: Recommendations from the American College of Physicians
Annals 2005 143: I-46. [Full Text]  



This article has been cited by other articles:


Home page
ANN INTERN MEDHome page
P. D. Phatak, H. L. Bonkovsky, and K. V. Kowdley
Hereditary Hemochromatosis: Time for Targeted Screening
Ann Intern Med, August 19, 2008; 149(4): 270 - 272.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Waalen, V. J. Felitti, T. Gelbart, and E. Beutler
Screening for hemochromatosis by measuring ferritin levels: a more effective approach
Blood, April 1, 2008; 111(7): 3373 - 3376.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
C. M. Francucci, C. Gatti, A. Camilletti, P. Fiscaletti, R. Caudarella, and M. Boscaro
Hypogonadism and Reduced Bone Mineral Density in Heterozygous H63D Mutation in the HFE Gene: An Unusual Presentation of Hereditary Hemochromatosis
J Androl, January 1, 2007; 28(1): 21 - 26.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
U.S. Preventive Services Task Force*
Screening for hemochromatosis: recommendation statement.
Ann Intern Med, August 1, 2006; 145(3): 204 - 208.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
E. P. Whitlock, B. A. Garlitz, E. L. Harris, T. L. Beil, and P. R. Smith
Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force.
Ann Intern Med, August 1, 2006; 145(3): 209 - 223.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
E. McPherson
Genetic diagnosis and testing in clinical practice.
Clin. Med. Res., June 1, 2006; 4(2): 123 - 129.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
D. W. Swinkels, M. C.H. Janssen, J. Bergmans, and J. J.M. Marx
Hereditary Hemochromatosis: Genetic Complexity and New Diagnostic Approaches
Clin. Chem., June 1, 2006; 52(6): 950 - 968.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
Correction: Screening for Hereditary Hemochromatosis: A Clinical Practice Guideline from the American College of Physicians
Ann Intern Med, March 7, 2006; 144(5): 380 - 380.
[Full Text] [PDF]


Home page
JWatch GeneralHome page
Screening for Hemochromatosis: ACP Practice Guideline
Journal Watch (General), October 18, 2005; 2005(1018): 1 - 1.
[Full Text]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2005 by the American College of Physicians.